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α-Synuclein vaccination modulates
regulatory T cell activation and microglia
in the absence of brain pathology
Josefine R. Christiansen1,2,3, Mads N. Olesen1,3, Daniel E. Otzen4, Marina Romero-Ramos2,3
and Vanesa Sanchez-Guajardo1,3*
Abstract
Background: Passive and active immunization with α-synuclein has been shown to be neuroprotective in animal
models of Parkinson’s disease. We have previously shown that vaccination with α-synuclein, long before α-synuclein-
induced brain pathology, prevents striatal degeneration by inducing regulatory T cell infiltration in parenchyma and
antibody deposition on α-synuclein overexpressing neurons. However, the effect of peripheral α-synuclein on the
immune system is unknown, as are the mechanistic changes induced in the CD4 T cell population during successful
neuroprotective animal studies. We have studied the changes induced by vaccination with α-synuclein in the CD4 T
cell pool and its impact on brain microglia to understand the immune mechanisms behind successful vaccination
strategies in Parkinson’s disease animal models.
Methods: Mice were immunized with WT or nitrated α-synuclein at a dose equivalent to the one used in our previous
successful vaccination strategy and at a higher dose to determine potential dose-dependent effects. Animals were
re-vaccinated 4 weeks after and sacrificed 5 days later. These studies were conducted in naive animals in the absence
of human α-synuclein expression.
Results: The CD4 T cell response was modulated by α-synuclein in a dose-dependent manner, in particular
the regulatory T cell population. Low-dose α-synuclein induced expansion of naive (Foxp3 + CCR6-CD127lo/
neg) and dopamine receptor type D3+ regulatory T cells, as well as an increase in Stat5 protein levels. On
the other hand, high dose promoted activation of regulatory T cells (Foxp3CCR6 + CD127lo/neg), which were
dopamine receptor D2+D3-, and induced up-regulation of Stat5 and production of anti-α-synuclein antibodies.
These effects were specific to the variant of α-synuclein used as the pathology-associated nitrated form induced
distinct effects at both doses. The changes observed in the periphery after vaccination with low-dose α-synuclein
correlated with an increase in CD154+, CD103+, and CD54+ microglia and the reduction of CD200R+ microglia. This
resulted in the induction of a polarized tolerogenic microglia population that was CD200R-CD54CD103CD172a+ (82 %
of total microglia).
Conclusions: We have shown for the first time the mechanisms behind α-synuclein vaccination and, importantly, how
we can modulate microglia’s phenotype by regulating the CD4 T cell pool, thus shedding invaluable light on the
design of neuroimmunoregulatory therapies for Parkinson’s disease.
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Background
Parkinson’s disease (PD) is characterized by the loss of
dopaminergic neurons in substantia nigra and the pres-
ence in surviving neurons of pathological α-synuclein
(α-syn) aggregates termed Lewy bodies. Great effort has
been put into understanding the role of α-syn in PD eti-
ology and how to avert its detrimental effects. Several
strategies have been designed to prevent neuronal α-syn
accumulation or enhance clearance of α-syn aggregates
in PD-like animal models. Some of these strategies have
been designed to harness the adaptive immune system,
either through generation of α-syn-specific antibodies to
clear the α-syn deposits [1, 2] or via T cells in order to
tip the adaptive immune response into a Foxp3+ regula-
tory T (Treg) cell phenotype [3, 4]. However, the actual
effect that α-syn vaccination has on the peripheral adap-
tive immune system has not yet been investigated.
One of the characteristics of PD is the neuronal loss in
substantia nigra and the consequent overt decrease in
dopamine release. Interestingly, an overlooked aspect of
the disease is the effect this lack of dopamine has on the
immune system, as T cells express dopamine receptors
(DRs) and the dopamine transporter [5–10]. Out of the
five DRs, the type expressed by CD4 T cells appears to
depend on the type of effector cell they differentiate into
(i.e., Th1 vs. Th2) (reviewed in [11, 12]). Dopamine sig-
naling influences the type of effector CD4 T cell gener-
ated, and its effect is dependent on whether dopamine is
present when the T cell encounters its cognate antigen
for the first time or as an effector/memory cell (reviewed
in [13]). The concentration of dopamine in serum is esti-
mated to be 10 pg/ml [5], but this is increased locally
when T cells encounter dendritic cells and/or Treg cells,
as both of these cell types produce dopamine [14–16].
Dopamine is able to oxidize α-syn and induce generation
of toxic oligomeric species (for a review see [17]). At the
same time, α-syn is present in serum and +cerebrospinal
fluid (CSF), although the change in α-syn levels during
PD is still controversial. Data exist showing α-syn in-
crease [18] or decrease [19] in serum; as regards CSF,
there is an initial consensus of its decrease in synuclei-
nopathy patients [19]. However, there is an agreement
that α-syn can be released from cells in its natural un-
folded status or abnormally oligomerized [20–22]. Fur-
thermore, anti-α-syn antibodies are found in serum,
suggesting that α-syn is eliciting a sterile immune re-
sponse in the peripheral immune system [23–25]. Sterile
immune responses have been observed in Alzheimer’s
disease and relate to early, non-TCR-mediated responses
that result in inflammation in the absence of a pathogen.
Thus, discerning how α-syn affects DR expression on T
cells is of vital interest if we want to develop effective
immunoregulatory therapies for PD, as T cells may not
be responding the same way as in healthy conditions,
and/or they may be altered by the dopamine replace-
ment drugs currently used for PD treatment such as L-
dopa. There is, in fact, accumulating evidence that the
peripheral immune system in PD patients is affected
[26–34], that α-syn is expressed in T cells [35], and that
dopamine influences α-syn oligomerization and toxicity
[36–39].
We have previously shown that vaccination with hu-
man α-syn (150 μg in 200–225g rats) 10 weeks before
the onset of α-syn-induced brain pathology resulted in
protection against neuronal pathology, which coincided
with infiltration of Tregs into the brain parenchyma [3].
Our study contrasted with the adverse effect seen on 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-in-
duced neuronal pathology when the adaptive immune
system was exposed to the pathology-related nitrated α-
syn (Nα-syn) [40, 41]. These studies raised the question
as to how α-syn variants change the CD4 T cell popula-
tion in order for it to respond differently when chal-
lenged with neuronal overexpression/accumulation of α-
syn and how this response is modified by pathology-
associated modifications of α-syn. This was especially in-
teresting since at the time of α-syn overexpression in
our previous study (10 weeks post vaccination), the per-
ipheral immune system was no longer active, suggesting
that a recall adaptive immune response was mounted.
Additionally, it remained unclear if vaccination per se
had affected microglia or if the observed changes in
microglia were mediated by the peripheral immune sys-
tem upon α-syn accumulation. We elucidate herein the
mechanisms behind our previous successful α-syn vac-
cination strategy to slow/avert α-syn-induced neuronal
pathology, in particular, its effects on modulating the
CD4 T cell pool and its impact on brain microglia, and
compare them to the effects caused by the pathology-
associated variant Nα-syn.
Methods
Animals and vaccination strategy
A total of 58 10-week-old Foxp3-IRES-mRFP (FIR) mice
(C57BL/6 background) [42] equally distributed between
sexes were used divided into six groups of n = 8–10 ani-
mals per group. No statistical differences due to animal
gender were observed throughout the project. The
Foxp3-RFP mice were a kind gift from Prof. Antonio A.
Freitas, Pasteur Institute, France. Our vaccination strat-
egies consisted of recombinant human monomeric α-syn
or its nitrated variant (Nα-syn), as this pathology-
associated modification is known to exacerbate brain
pathology. Mice were vaccinated with 15μg (the dose for
mice equivalent to that used in our previous study in
rats) or 100-μg protein (to assess dose effect) and 150 μl
of complete Freund’s adjuvant subcutaneously on their
back at the level of the base of the tail (total volume
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300 μl). Four weeks after, the animals were again
injected with the same amount of protein in incomplete
Freund’s adjuvant. Five days after the second
immunization, the animals were killed for analysis
(Fig. 1). As control groups we also included the follow-
ing: naive (not immunized, as a baseline to be able to de-
termine if any immune processes took place) and
adjuvant (only immunized with Freund’s adjuvant, to as-
certain whether any differences were due to α-syn vari-
ants and not the adjuvant). The animals were distributed
into eight independent experiments, with animals from
different experimental groups included in each experi-
ment; all groups contain animals of at least three inde-
pendent experiments. Animal permits to perform the
experiments have been approved by the Animal Inspect-
orate. All experimental animal work was conducted ac-
cording to Danish regulations (Law no. 253, 08 03 2013,
Executive order no. 88, 30 01 2013) in agreement with
European Union directive (2010/63/EU) and under the
guidance of the veterinarian of the Faculty of Health,
Aarhus University.
Protein preparations
Human recombinant α-syn was prepared as published
before [43]. A fraction of the α-syn was nitrated in our
laboratory following the protocol from Reynolds et al.
[4]. Nitration was subsequently verified by Western blot
(≥98 % of total α-syn) and mass spectrometry (kindly
performed by Dr. Steen Vang Petersen, Department of
Biomedicine, Aarhus University). All protein solutions
were diluted at 1 μg/μl in isotonic NaCl at the time of
injection to obtain a volume of 150 μl/mouse of protein
solution.
Lymph node cell preparation
At the time of death, the inguinal, axillar, and brachial
lymph nodes were pooled per animal and single cell
suspensions were made in complete medium (RPMI-glu-
tamax with 10 % fetal calf serum (FCS), HEPES and
penicillin/streptomycin, all from GIBCO). Cells were fil-
tered through a 100-μm mesh and washed in 10 ml
medium. After centrifugation (400g for 10 min), the cells
were resuspended in 1 ml complete medium. An aliquot
was taken for cell counting, and 100 μl were taken for
flow cytometry analysis. The remaining cells were plated
on round bottom plates and let to rest in an incubator
for 6 h, after which the medium was recovered, and cells
were lysed in complete lysis buffer (one cOmplete Mini
protease inhibitor tablet, Roche Diagnostics and two
phosSTOP tablets, Roche Diagnostics, per 10 ml lysis
buffer: 10 mM Tris-base, 150 mM NaCl, 0.5 mM EDTA,
1 % IGEPAL CA-630 in deionized water). Both samples
were frozen at −20 °C until further analysis.
Microglia isolation
Brains were quickly dissected at the time of death and
homogenized in 1.4 ml of HEPES-buffered saline (HBS)
medium (GIBCO); 600 μl of Trypsin (50 mg/ml,
Trypsin-EDTA, SIGMA) were added and the mix was
put on a 37 °C water bath for 15 min. Two milliliters of
HBS medium and 800 μl of FCS (20 %) were added be-
fore centrifugation (200g for 4 min). The pellet was re-
suspended in 5 ml HBS and carefully pipetted to obtain
a single cell suspension. The sample was filtered (40 μm)
before centrifugation, and the pellet was resuspended in
2.3 ml 75 % Percoll (GE Healthcare, Sweden). Five milli-
liters of 25 % percoll followed by 3 ml PBS were layered
on top of the cell suspension, and the sample was centri-
fuged for 25 min at 800g. Microglia were recovered from
the interphase between the 75 and 25 % gradient and
washed with 15 ml PBS. After centrifugation, the pellet
was resuspended in 100 μl PBS for fluorescence-
activated cell sorting (FACS) analysis.
Fig. 1 Schematic diagram of the experimental design. Foxp3-RFP mice were immunized with 15 or 100 μg of recombinant human α-syn in
complete Freund’s adjuvant and re-immunized after 4 weeks with the same amount of protein in incomplete Freund’s adjuvant. Five days later,
the animals were killed and the lymph nodes and brain dissected for analysis. Blood was obtained to determine antibody load in serum. A single
lymph node cell suspension was made and either analyzed by flow cytometry or incubated for 6 h, after which the cells were lysed for analysis
by Western blot. Microglia were isolated from brains and analyzed by flow cytometry. Alternatively, the animals were perfused at the time of
death and brains processed for immunohistochemistry
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Flow cytometry
All samples were plated on a 96-conical-well plate and
centrifuged 4 min at 400g. The cells were then incubated
for 10 min with 30 μl/well Fc block, centrifuged again,
and resuspended in 30-μl antibody mix (Additional file
1: Table S1) for 10 min incubation in the dark. After
washing, 30 μl/well of secondary antibody mix was
added, and the cells were incubated for 10 min in the
dark, washed twice, and resuspended in 200 μl buffer.
All incubations were done on ice, and all the washes
(100 μl, 300g), and antibody mix were done in PBS with
0.5 mM EDTA, penicillin/streptomycin, 2 % FCS with-
out Ca2+ and Mg2+. Sample data was acquired in a FACS
ARIA III (with four lasers) interphased to FlowJo soft-
ware for analysis. All samples were gated first on live
cells according to their FSC vs. SSC, doublets were re-
moved by plotting FSC-H vs. FSC-A, and either 5000
CD3CD4Foxp3-RFP+ or 10,000 CD11b+-gated cells
were acquired for analysis. The gates of positive CCR6,
CD103, CD25, CD127, DR-D2, and DR-D3 cells were
determined by the use of Fluorescence Minus One
(FMO) for each of these antibodies.
Immunohistochemistry
Three mice per group were killed with an overdose of
pentobarbital and, upon respiratory arrest, perfused
through the ascending aorta with ice-cold saline solution
(without heparin) followed by 4 % paraformaldehyde.
The brains were post-fixed in paraformaldehyde for 4 h
and left for cryoprotection in a 25 % sucrose solution.
The brains were then sliced into 40-μm-thick coronal
sections and separated into four full brain series. Immu-
nohistochemistry was performed on a full series for α-
syn, and in one third of a series for CD11b, anti-mouse
IgG, major histocompatibility complex (MHC) II, and
CD4 (for antibody specification see Additional file 1:
Table S1). Free-floating sections were quenched for
20 min in a solution of 3 % hydrogen peroxide and 10 %
methanol. One hour of pre-incubation with 5 % appro-
priate normal serum was followed by overnight incuba-
tion at room temperature with the primary antibody in
2.5 % normal serum. Thereafter, the sections were incu-
bated for 2 h with the appropriate biotinylated secondary
antibody in 1 % normal serum. Sections were further in-
cubated 1 h with avidin-biotin-peroxidase complex in
PBS (ABC Elite, Vector Laboratories, Burlingame, CA).
Sections were rinsed three times in potassium-
phosphate buffer (KPBS) between each incubation
period. All incubation solutions contained 0.25 % Triton
X-100 in KPBS. Visualization was done using 3,3-diami-
nobenzidine (DAB) and 0.1 % of hydrogen peroxide for
α-syn visualization and 0.01 % for the others. The sec-
tions were mounted on chrome-alum-coated glass slides
and cover-slipped. Sections were analyzed by an
observer blind to the identity of the samples on a Zeiss
LSM710 microscope at ×1.25, ×10, and ×40; photo-
graphs were taken with VisioPharm software.
SDS-PAGE and Western blot
Prior to SDS-PAGE and Western Blot analyses, the con-
centration of protein in the samples was determined using
a bicinchoninic acid assay with a bovine serum albumin
standard curve. One hundred microgram of protein was
mixed with an SDS- and DTE-containing loading buffer
prior to boiling and loading on an 8 % Bis-Tris gel (VE
vertical electrophoresis system, Hoefer). After separation,
proteins were blotted onto ethanol pre-activated polyviny-
lidene fluoride membrane (PVDF) membranes (GE
Healthcare) for 1.5 h in an ethanol-containing buffer using
the Hoefer system. Thereafter, membranes were blocked
with 5 % skimmed milk in Tris-buffered saline with
0.05 % Tween-20 (TBS-T) for 1 h at room temperature
and then incubated with a primary antibody (Additional
file 1: Table S1) in 1 % skimmed milk TBS-T solution
overnight at 4 °C. On the following day, the membranes
were washed three times for 5 min with TBS-T and
incubated with the appropriate horseradish peroxidase
(HRP)-conjugated secondary antibody (Additional file 1:
Table S1) in 1 % milk in TBS-tween for 2 h at room
temperature. The blots were visualized by enhanced
chemiluminiscence (Amersham ECL Western Blotting de-
tection reagents, GE Healthcare) using a Fuji LAS-4000
ImageReader. Subsequently, blots were stripped for
30 min at 50 °C and incubated with a different primary
antibody. The intensities of the protein bands were quan-
tified using MultiGauge software and normalized to the
level of β-actin in the sample. The Foxp3 antibody
detected two bands at 50 kDa in some samples, which is
believed to present a full-length isoform and an isoform
lacking exon 2, respectively. Both Fopx3 variants have
been shown to function as inhibitors of CD4 T cell activa-
tion [44], and thus when quantified, the intensities of both
Foxp3 bands in a sample were added up.
Anti-α-synuclein antibody titration by ELISA
Prior to perfusion, retro-orbital blood samples were
taken and allowed to coagulate for 24–48 h at 4 °C and
centrifuged for 10 min at 400g. Serum was isolated and
stored at −20 °C until analysis. The serum titer of anti-
α-syn antibodies was analyzed by indirect ELISA. Maxi-
Sorp 96-well ELISA plates (Thermo Fisher Scientific)
were coated overnight at 4 °C with 200 ng/well recom-
binant human α-syn (the same used to immunize the
animals) in 100 mM carbonate/bicarbonate buffer, pH
9.6. After three washing steps using PBS with 0.05 %
Tween-20 (PBS-T), wells were blocked for 2 h with
150 μL 0.2 % bovine serum albumin and 0.05 % Tween-
20 in PBS (referred to as “blocking buffer”). Next,
Christiansen et al. Journal of Neuroinflammation  (2016) 13:74 Page 4 of 19
100 μL of serum samples serially diluted in blocking
buffer were added for overnight incubation at 4 °C.
Additionally, monoclonal mouse anti-human α-syn IgG
(Covance, clone 4B12) was used from 1:1000 to
1:128,000 to allow generation of a standard curve. All
dilutions were run in duplicates. After rinsing in PBS-T,
wells were incubated for 2 h at room temperature with
100 μL horseradish peroxidase-conjugated monoclonal
rabbit anti-mouse IgG in blocking buffer. As negative
controls, either standard antibody or secondary antibody
was omitted during incubations. Following three washes
in PBS-T, plates were allowed to develop for 20–25 min
with 100 μL 1-Step Ultra TMB-ELISA Substrate
(Thermo Fisher Scientific) and reaction stopped by
addition of 100 μL ready-to-use sulfuric acid Stop Solu-
tion (Thermo Fisher Scientific). Absorbances at 450 nm
were read on a VersaMax plate reader (Molecular
Devices). A log decay curve was fitted within the linear
range (1:2000–1:48,000). This fit and absorbance mea-
sured from serum diluted at 1:400 or 1:3200 were used
to calculate serum anti-α-syn titer (μg/μL).
Statistical analysis
Statistical comparison of data was performed using
Prism 6 (GraphPad Software, Inc). A parametric, one-
way ANOVA assuming no matching/pairing of data
and equal SD was done for all studies. When signifi-
cant, it was followed by multiple comparisons with a
Tukey pos hoc analysis, or in the case of the distribu-
tion analysis (Figs. 5 and 6), a Fisher’s least significant
difference (LSD) to determine significant changes be-
tween groups. Significance was accepted at the 95 %
probability level.
Results
We immunized naive Foxp3-RFP mice with human
recombinant α-syn at two different doses: low,
equivalent to the one used in our previous study, and
high, to determine potential dose-dependent effects.
As controls, we immunized additional groups of mice
with adjuvant alone to determine its contribution to
the response as it has been shown to be protective
per se in PD animal models [45, 46] and the
pathology-associated Nα-syn to show that the re-
sponse is specific for wild type α-syn. Animals were
re-immunized 4 weeks after the original vaccination
and killed 5 days later to study the T cell response
and changes in brain microglia (Fig. 1). A group of
naive animals was included as an additional control
group to determine the baseline of all immunological
parameters, such as cell numbers, percentage and dis-
tribution of cell populations, and activation states.
This allows the determination of any immunological
change as compared to the homeostatic state, indica-
tive of an immune response.
α-Synuclein vaccination decreases the percentage of
CD3+CD4- T cells and increases the number of
CD3CD4Foxp3+ cells
The percentages of live CD3+CD4+ and CD3+CD4-
cells (assumed CD8+ lymphocytes), as well as the per-
centage of Foxp3+ cells within the CD4 T cell pool in
lymph nodes, were assessed by flow cytometry (Fig. 2a).
The number of T lymphocytes was generally increased
to a highly variable degree upon vaccination, but only
low-dose Nα-syn gave a significant increase in CD3CD4
+ cells as compared to naive (Fig. 2b). However, vaccin-
ation with low or high dose of α-syn resulted in a signifi-
cant reduction of the percentage of CD3+CD4- cells
(Fig. 2c), indicating that the response was mainly of the
CD4 T cell type. Furthermore, the number of
CD3CD4Foxp3+ cells was significantly increased upon
low-dose vaccination independently of the α-syn variant
(Fig. 2d).
α-Synuclein affects the naive/activated/memory distribution
of Foxp3+ T cells
To examine the effect of α-syn on T cell activation and
survival, the number of cells expressing the IL-2Ra
(CD25) within the CD3+CD4+ T cell pool was estimated
by flow cytometry (Fig. 3a). The percentages of activated
CD3+CD4+ T cells 5 days after re-vaccination were sig-
nificantly different from naive when the animals were
vaccinated with low-dose α-syn or adjuvant alone
(Fig. 3b). Nα-syn, on the other hand, showed a tendency
to abolish this CD25 up-regulation (induce activation),
especially at high dose. Vaccination, however, had no ef-
fect on the survival capacity of Foxp3+ T cells (Fig. 3c).
We also measured IL-7Ra (CD127, Fig. 3d), as a marker
of T cell effector/memory survival (Fig. 3e) and Treg acti-
vation (Fig. 3f), but vaccination had no effect on these
populations. However, when the distribution between
naive (CD127lo/negCCR6-), activated (CD127hiCCR6-),
and memory (CD127lo/negCCR6+) Foxp3+ T cells was
analyzed (Fig. 3g), a significant increase in the percentage
of naive Foxp3+ T cells was observed in animals vacci-
nated with low-dose α-syn with respect to naive and both
α-syn variants at high dose (Fig. 3h). High-dose α-syn, on
the other hand, expanded the memory fraction of Treg as
compared to adjuvant and Nα-syn independent of the
dose. Nα-syn significantly increased the fraction of the
double-positive population irrespective of the dose when
compared to all other groups. Importantly, these changes
were significantly different to adjuvant (A, †, ≠ in Fig. 3),
thus indicating that it is a direct response to the α-syn
variant and not due to the administration of adjuvant.
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To our knowledge, the presence of both markers has
not been associated with any specific activation state or
function of the Treg population, and thus, this could in-
dicate that Nα-syn has switched off/inactivated the Treg
compartment.
α-Synuclein variants tend to modify the RORγt–Foxp3
balance and alter Stat protein expression
To determine whether α-syn modified the induction of
Th17 cells (autoimmune inflammation) and Tregs (toler-
ance), we measured the levels of their respective canon-
ical transcription factors RORγt and Foxp3. Additionally,
we looked at the levels of Stat3 and Stat5 and their
phosphorylation states because TGFβ/IL-6 and IL-2 sig-
nal through these molecules to induce, respectively, the
Th17 or Treg phenotype (Fig 4a). All immunizations
tend to increase Foxp3 levels compared to naive, but
only low-dose α-syn showed a clear trend to its up-
regulation as compared to naive (Fisher’s LSD, p =
0.0419), so the effect was probably due to the adjuvant
(Fig 4b). Vaccination with Nα-syn was the only strategy
that showed a trend to induce RORγt protein as com-
pare to naive (p = 0.08, Fisher’s LSD). No significant
changes in the protein level of Stat3 were observed
among the groups, despite clear trends towards modula-
tion of its phosphorylation (one-way ANOVA, p =
0.047); indeed, the ratio of phosphorylated Stat3 was sig-
nificantly increased by Nα-syn as compared to all other
groups (Fig 4b). Conversely, total Stat5 was significantly
modulated depending on vaccination strategy (one-way
ANOVA, p = 0.0002), although only the α-syn high-dose
group showed significance as compared to low-dose Nα-
syn. However, the level of Stat5 phosphorylation of the
α-syn high-dose group was significantly increased as
Fig. 2 T cell numbers in lymph nodes. Lymph node cells were analyzed by flow cytometry. a Representative dot plots of gated live cells, thereafter
gated for CD3+CD4+ and CD3+CD4-. The CD4+ fraction was further gated into Foxp3+ and Foxp3− cells. b Total number of CD3+CD4+ and CD3
+CD4- cells. c Percentage of CD4+ and CD4− cell in lymph nodes. d Total CD3+CD4+Foxp3+ cells within the total CD3+CD4+ cell population. One-
way ANOVA followed by Tukey HSD. Asterisk means different from naive. p < 0.05. All numbers are average + SD. N = 8–10, divided into three to five
independent experiments
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Fig. 3 IL-2Ra (CD25) and IL-7Ra (CD127) expression on CD3+CD4+ lymph node cells. Cells were gated for CD3+CD4+Foxp3- (i.e., Th) and CD3
+CD4+Foxp3+ (i.e., Treg) as in Fig. 2. Representative histograms showing the level of expression of IL-2Ra (a) and IL-7Ra (d) in Th (dark gray) and
Treg (light gray) T cell populations. Bar graphs showing the average percentage + SD of cells expressing CD25 (b, c) or CD127 (e, f). b, e CD3+CD4
+Foxp3- cells. c, f CD3+CD4+Foxp3+ cells. g Representative dot plot of CD3+CD4+Foxp3+ cells expressing CD127 and CCR6. h Bar graphs showing
the distribution of CD3+CD4+Foxp3+ cells (average percentage + SD) according to their expression of CD127 and CCR6. One-way ANOVA followed by
Tukey HSD. Asterisk means different from naive; A means different from adjuvant; dagger symbol means different from naive and adjuvant; closed circle
means different from high-dose α-syn and Nα-syn; open circle means different from the other α-syn variant independent of dose; not equal to symbol
means different from all; double dagger symbol means different from the other α-syn variant at a different dose; plus-minus sign means different from
the same α-syn variant at different dose. p < 0.05. N = 8–10, divided into three to five independent experiments
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compared to low-dose α-syn for both variants and to ad-
juvant (Fig 4b), indicating that the changes in phosphor-
ylation are due to the dose of α-syn and not the effect of
the adjuvant. Indeed, the level of Stat5 phosphorylation
of Nα-syn and adjuvant were significantly lower than the
naive group. Together, these data suggest that vaccin-
ation with α-syn increases Stat5 and its phosphorylation
in a dose-dependent manner.
α-Synuclein vaccination only generates antibodies against
α-synuclein at high dose
Serum was tested for anti-α-syn antibodies by ELISA
(Fig. 4c). Only vaccination with high-dose α-syn showed
a significantly higher serum titer of antibodies specific
for α-syn as compared to naive and low-dose Nα-syn.
This indicates that the immune response elicited by vaccin-
ation with a low dose of antigen did not involve a humoral
response and thus, most likely, did not result in activation
of the B cell pool by T cells, suggesting a suboptimal TCR
activation. At high dose, however, we achieved an antigen-
specific immune response against α-syn.
Dopamine receptors on CD4 T cells are affected by dose
and variant of α-synuclein
Dopamine is known to be a contributing factor in
lymphocyte regulation, and at the same time, dopamine
can form complexes with α-syn and increase its
oligomerization [37, 47–49]. We have looked at two DRs
known to have opposite effects on CD4 T cells (Fig. 5a):
DR-D2, which is associated with T cell regulatory functions,
Fig. 4 T cell differentiation. a Lymph nodes cells were incubated in vitro for 6 h without activation and thereafter lysed for analysis by western
blot as described in the “Methods” section. Representative blot for each protein studied. Band intensity was quantified and normalized to the
intensity of β-actin. b Bar graphs showing the average relative value + SD of normalized levels of protein in lymph node cell lysates (n = 3–5 samples/
group). c Bar graphs showing the average + SD titer of anti-α-syn antibodies in serum (μg/μL). All samples were done in duplicates (n = 3–5/group).
One-way ANOVA followed by Tukey HSD. Asterisk means different from naive; A means different from adjuvant; not equal to symbol means different
from all; double dagger symbol means different from the other α-syn variant at a different dose; plus-minus sign means different from the same α-syn
variant at different dose. p < 0.05
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and DR-D3, which is thought to induce pro-inflammatory
responses and has been implicated in the detrimental T cell
response in the MPTP model of PD [50, 51].
In general, vaccination induced a variable regulation of
the DRs. However, some effects were observed: low-dose
α-syn vaccination significantly decreased the DR double-
negative fraction of the Tregs cells as compared to all
other strategies, something also observed to a lesser ex-
tent in the adjuvant group (Fig. 5b). This correlated with
a non-significant increase in DR-D3 expression. Increas-
ing the dose of α-syn did not show a significant change
in the percentage of DR negative cells but a tendency to
increase DR-D2 at the expense of DR-D3. Nα-syn had a
tendency to decrease the number of Tregs expressing
DR-D2 and to increase the DR double-negative percent-
age independently of dose (one-way ANOVA, p = 0.07,
Fisher’s LSD different to other groups).
When looking at effector CD4 T cells (Fig. 5c), we saw
a similar decrease in the DR double-negative fraction as
a result of adjuvant and low-dose α-syn vaccination, but
in these populations, the tendency was to increase both
DR-D2 and DR-D3, while eliminating the double-
positive fraction. As for Tregs, Nα-syn abolished the ex-
pression of DR-D2.
α-Synuclein modulates the homing (CCR6) and tolerance
(CD103) capacity of CD4 T cells
To determine whether α-syn vaccination had modified
the capability of T cells to migrate to the brain, we
measured the expression of CCR6, a chemokine receptor
implicated in T cell brain homing in the animal model of
multiple sclerosis (EAE) [52]. We also looked at the ex-
pression of CD103, a lectin involved in cell-cell induced
tolerance and T cell extravasation (Fig. 6a) [53, 54]. The
fraction of cells within the Treg (Fig. 6b) and Th (Fig. 6c)
pools positive for any of these markers was variable but
always below 40 %.
Treg expression of these markers was affected in a dose-
and variant-dependent manner. Significant changes were
observed in the number of double-negative cells (CD103-
CCR6-), which were increased by adjuvant and Nα-syn
vaccinations independently of dose with a concomitant
significant reduction in CCR6+ cells. In contrast, high
dose increased the CCR6+ fraction with respect to adju-
vant and Nα-syn independently of dose, leading to a sig-
nificant decrease in the double-negative fraction (Fig. 6b).
Interestingly, we observed that CD103 and CCR6 ex-
pression was mainly observed in DR-D2+ and DR-D3+
cells (though there is no direct correlation with DR ex-
pression), as only Th cells positive for these DRs
expressed these markers (Fig. 6e, g), and the fraction of
DR-D2-D3- Tregs expressing these markers was below
13 % (Fig. 6h). DR-D2 expression was mainly associated
with expression of CCR6 (Fig. 6d, e), and only Tregs
showed modulation of its expression upon vaccination.
High-dose α-syn significantly induced CD103 on Tregs
as compared to all other groups (Fig. 6d), while Nα-syn
independently of dose significantly reduced CCR6
Fig. 5 Dopamine receptor D2 and D3 expression on CD3+CD4+ cells. Th and Treg were gated as described, and the percentage of cells
positive for dopamine receptor DR-D2 and DR-D3 were determined. a Representative dot plots for DR-D2 and DR-D3 co-expression. The
relative percentages of DR-D2+, DR-D3+, double-positive (DR-D2+D3+), and double-negative (DR-D2-D3-) cells within the Treg (b) and Th
(c) populations are shown as average + SD. One-way ANOVA followed by Fisher’s LSD. not equal to symbol means different from all. p <
0.05. n = 8–10, divided into three to five independent experiments
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expression. DR-D3+ Tregs (Fig. 6f ), on the other hand,
expressed CCR6 but vaccination induced its down-
regulation and promoted CD103 expression. This was
mainly independent of vaccination strategy and thus
most likely an effect of the adjuvant, except at high-dose
α-syn, which induced CD103 without reducing CCR6 in
an adjuvant-independent manner.
Vaccination induces microgliosis specifically in
substantia nigra
To determine if α-syn vaccination resulted in activation of
brain microglia, a series of coronal sections throughout
the brains were stained for CD11b as a marker of micro-
glia. An observer, blind to the sample’s identity, analyzed
the sections to assess any change in the morphological
profile of CD11b+ microglia. With the exception of sub-
stantia nigra (Fig. 7), selected regions of the brain (cortex,
hippocampus, and striatum) showed no overt difference
as compared to naive animals (Additional file 2: Figure
S1). In substantia nigra, however, animals that received ad-
juvant (Fig. 7e) presented microglia with enlarged soma,
as well as elongation and hyper-ramification of their pro-
cesses as compared to naive animals. These morphological
differences were also observed in α-syn low dose (Fig. 7a),
but not in α-syn high dose (Fig. 7c), suggesting that al-
though microgliosis may be an effect of the adjuvant, the
dose of the antigen also plays a role in how brain micro-
glia reacts. Indeed, Nα-syn also induced changes in micro-
glia morphology (Fig. 7b, d), but these changes were
clearly different from those induced by adjuvant and α-syn
as the soma was constricted, with barely any cytoplasm
around the nucleus, and the processes were not branched.
We also analyzed the expression of MHC II in adjacent
sections, but no clear difference were observed among
groups, with only occasional ramified MHC II+ microglia-
like cells found in parenchyma in all groups (Additional
file 3: Figure S2A). Indeed, most of the MHC II+ staining
was associated to blood vessels in all groups (Additional
file 3: Figure S2B).
We did observe sporadic microglia-like cells positive
for CD4 (Additional file 3: Figure S2C&D) and blood
vessel positive staining (Additional file 3: Figure S2E).
However, no infiltrated CD4+ T cell (small, round, and
un-ramified) were observed in brain parenchyma,
suggesting that microglia activation was not induced by
direct T cell-microglia interactions at the time of the
sacrifice. This is not surprising, as there is neither the
antigen nor a pathological process ongoing in the brain
and thus no cues to make T cells home to the brain. Fur-
thermore, this supports our hypothesis that the homing
of CD4 T cells into the brain previously reported by us
in the rAAV-α-syn PD model is the direct consequence
of α-syn-induced pathology in brain.
(See figure on previous page.)
Fig. 6 Expression of CCR6 and CD103. Cells were gated as before for CD3+CD4+Foxp3- (Th) and CD3+CD4+Foxp3+ (Treg) and thereafter for
dopamine receptor expression: D2 (DR-D2+), D3 (DR-D3+) or double-negative (DR-D3-D2-). The expression of CCR6 and CD103 was determined
in each of these populations. a Representative dot plot showing CCR6 and CD103 co-expression in Treg cells un-gated for DR. b–g Bar graphs
representing the average percentage + SD of cells expressing CCR6 and CD103 in the total Treg (b) and Th (c) cell populations and in cells gated
for DR-D2 (d, e) and DR-D3 (f, g). h Bar graph showing the average percentage + SD of CCR6+ and CD103+ cells in Treg cells negative for DR
expression. One-way ANOVA followed by Fisher’s LSD. Asterisk means different from naive; A means different from adjuvant; open circle means
different from the other α-syn variant independent of dose; not equal to symbol means different from all; plus-minus sign means different from
the same α-syn variant at different dose; dollar sign means different from the other α-syn variant at the same dose. p < 0.05. N = 8–10, divided into
three to five independent experiments
Fig. 7 CD11b immunopositive microglia in substantia nigra. A series
of coronal brain sections were immunostained with anti-CD11b
antibody to assess changes in microglia cell number or morphology.
Photos show representative substantia nigra images from animals
having received low-dose protein (a, b), high-dose protein (c, d), and
adjuvant (e) and from a naive mouse (f). Scale bar in e applies to all,
10 μm (n = 3, one experiment)
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α-Synuclein does not cross the blood-brain-barrier and
deposit in the brain
An obvious question when considering the effect of α-
syn vaccination on microglia is whether α-syn crossed
the blood-brain-barrier and deposited in the brain; if so,
the changes in microglia might then not be the result of
acting on the peripheral immune system but rather a
direct consequence of α-syn accumulation in the brain
parenchyma. When representative brains sections were
immunostained for human α-syn 5 days after the last
immunization, we were not able to detect any positive
staining for the human protein throughout the brain in
any group, and they were indistinguishable from naive
animals (Additional file 4: Figure S3). We also stained
series of brain sections for anti-mouse IgG, but with the
exception of sporadic staining in the hippocampus of the
α-syn high dose, no apparent IgG deposition was ob-
served in brain parenchyma, confirming that α-syn-
specific antibodies were not generated, and those gener-
ated at α-syn high dose did not find their antigen in
brain (Additional file 3: Figure S2F). Indeed, blood ves-
sels in all groups stained positive for IgG (Additional file
3: Figure S2G), indicating that antibodies did not cross
the brain-blood-barrier.
α-Synuclein low dose induces the polarization of brain
microglia into a specific phenotype
We were particularly interested in elucidating whether by
altering the peripheral T cell pool we would modify the
microglia phenotype. Total brain microglia were isolated
from immunized mice (Fig. 8a) and stained with markers
related to tolerance induction (Fig. 8b) or to interactions
with the adaptive immune system (Fig. 8c) (see Additional
file 1: Table S1 for function of each marker).
The percentage of microglia expressing the different
markers varied depending on the dose and variant of α-
syn. While CD154+ (CD40L) cell count was increased
by α-syn independently of the dose, it only increased the
percentage of CD103+ cells at low dose and CD4+ and
CD11c+ cells at high dose (Fig. 8b, c), the latter being
significantly higher than adjuvant. Nα-syn also showed a
dose-dependent effect increasing the percentage of
CD154+ and CD103+ cells at low dose (thus behaving as
α-syn), but at high dose, it increased CD172a+ and CD4
+ cells (significantly different from adjuvant), while de-
creasing CD11c+ percentage, showing variant specificity
(Fig. 8b, c). All these effects were antigen-specific as ad-
juvant did not show any significant changes in these
markers with respect to naive. The only change that
seemed to be adjuvant-induced was the increase in
CD54 (ICAM-1), which was similar across all vaccin-
ation strategies (Fig. 8c).
We analyzed the correlation between markers to de-
termine if a specific microglia response was induced or
if a plethora of distinct microglia were present (Fig. 8d–
i). We observed that the vaccine-induced modulation of
these markers resulted in the polarization of microglia
into specific phenotypes different to the ones observed
in the naive and adjuvant groups, where there is barely
any correlation between markers implying a broad var-
iety of microglia. Thus, the correlation of markers is due
to the variant and its dose and not the effect of the adju-
vant; low-dose α-syn, independently of variant (nitrated
or not), induced a distinct type of brain microglia
(CD54CD172aCD103+ CD200R-, 87 % of total), but
when the dose of the α-syn was increased, this
polarization of the microglia is affected by the variant :
Nα-syn gave rise to a distinct phenotype by inducing the
expression of CD4 on practically all brain microglia
(97.32 %), while high-dose α-syn resulted in the loss of
microglia polarization. Unfortunately, this CD4 expres-
sion was not detectable by immunohistochemistry, sug-
gesting that its level of expression must be too low to be
visible using this technique (i.e., how many CD4 mole-
cules/microglia).
Discussion
Great attention has been put into α-syn-based
immunization therapies in PD, but little is known about
the effect that α-syn, an autologous protein, has on the
immune system. Indeed, we have previously shown that
vaccination with low-dose α-syn and Freund’s adjuvant
results in protection against α-syn-induced striatal path-
ology [3], but the mechanism behind this successful ap-
proach was unclear. Therefore, we have herein
immunized naive Foxp3-RFP mice with human α-syn at
two doses, low (15 μg, a dose equivalent to that used in
rats in our previous study) or high (100 μg, to assess
dose effect), with Freund’s adjuvant as before to deter-
mine the mechanism behind the successful vaccination
approach. We have used mice instead of rats, as in our
previous study, in order to benefit from the transgenic
Foxp3-RFP strain and so easily follow Treg cells.
We examined the effect that α-syn had on the periph-
eral CD4 T cell pool and central nervous immune sys-
tem (microglia) 5 days after the second immunization.
Importantly, our study was undertaken in the absence of
any human α-syn expression, pathology, or deposition in
the brain.
α-Synuclein modulates the naive/activated/memory
frequencies of regulatory T cells
α-Syn immunization specifically changed the expression of
CD127 and CCR6 in the Foxp3+ Treg cell population.
Low-dose α-syn vaccination significantly increased the
naive population (CD127-CCR6+) suggesting the gener-
ation of antigen-specific Tregs in the periphery; this expan-
sion was reflected in the increase of total Foxp3+ cells. α-
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Syn at high dose had a tendency to induce memory Tregs,
as it increased the fraction of CD127lo/negCCR6-Foxp3+
cells, and this correlated with an increase in CD103+ cells
and increased phosphorylation of Stat5. IL-7R (CD127) is
highly expressed by activated Tregs and correlates with the
expression of CD103, ICOS, phospho-Stat5, and enhanced
survival capacity [55]. In vitro, IL-7 signaling potentiates
Treg function by increasing Foxp3, CD25, and CTLA-4 ex-
pression resulting in the down-regulation of its receptor
CD127 [56]; these CD127lo memory Tregs are strongly
suppressive [57]. Here, it is difficult to know whether the
high-dose α-syn immunization induced the activation of
the natural Treg pool or if newly generated α-syn-specific
Tregs were activated due to the higher concentration of α-
syn.
The peripheral immune system is used to sensing α-
syn, which is constitutively secreted by enteric neurons
in vitro [58], and it is naturally expressed in erythrocytes
[59] and most immune cells [60]. With age, α-syn accu-
mulates in healthy human peripheral blood mononuclear
cells (PBMCs), an accumulation that is greater in PD pa-
tients, and compromises survival and function of these
cells [61, 62]. Hence, the dose of α-syn, which the im-
mune system encounters varies with age, in particular in
PD patients, potentially affecting the way the immune
system reacts to it. Indeed, it is known that a low anti-
gen dose with suboptimal antigen presentation induces
Tregs in the periphery and expands them [63]. Thus,
our results suggest that low α-syn levels may expand the
naturally occurring Tregs specific for the endogenous α-
syn. This is supported by the non-significant increase in
Foxp3 protein levels and the lack of antibodies against
α-syn, suggesting a suboptimal TCR-mediated activation
of CD4 T cells. At higher doses, α-syn may induce Treg
activation (supported by the increased phospho-Stat5).
When a pathological threshold of α-syn is attained, at
which point the protein has likely been modified, toler-
ance towards α-syn may break, and a detrimental im-
mune response that favors autoimmune inflammation
(Th17) may be induced. Indeed, in previous work by
Gendelman’s group, they immunized mice with 50 μg of
nitrated α-syn, which resulted in the induction of Th17
T cells and defective Treg [40]. Thus, our previous vac-
cine approach proved beneficial because we increased
tolerance towards α-syn through the expansion of naive
Tregs. Our new results show that the dose employed is
important, as increasing the dose results in a different
immune response, and this might not prove protective.
Together, the evidence suggests that in a pathological
scenario such as PD, as brain pathology and the patho-
logical state of α-syn progress, different Treg responses
may be induced. These Tregs will have different capabil-
ities to migrate to the brain, judging by their CCR6 ex-
pression. CCR6 is expressed by all Th17 T cells
(autoimmune inflammation) and a subset of Tregs (ef-
fector/memory [64]), and in both cases, its expression is
required to cross the blood-brain-barrier ([65], reviewed
in [66, 67]).
α-Synuclein-induced immune changes show association
with dopamine signaling
It is well established that dopamine regulates the adap-
tive immune system (for a review see [11–13, 68, 69]).
Interestingly, dopamine and α-syn can modify each
other: interaction between oxidized dopamine and α-syn
results in toxic compounds [36–39], which may puta-
tively signal to the immune system. Furthermore,
dopamine-modified α-syn does not induce TNF and ni-
tric oxide by microglia, but instead has an anti-oxidant
effect, something not seen with the oligomeric α-syn,
further supporting the idea that dopamine and α-syn
interaction can be meaningful to pathology [70]. In turn,
α-syn oligomerization is promoted by dopamine, pre-
venting its fibrillization (for a review see [17]). In healthy
humans, it is estimated that there is 10 pg/ml of dopa-
mine in serum, rising to 80 pg/ml during sickness, and
such concentrations are able to alter T cell physiology
[5]. DR signaling has been associated with particular T
cell cytokine profiles depending on the specific dopa-
mine receptor type involved, and particularly influences
the Th17 vs. Treg balance [15, 16, 71–73]. We measured
expression levels of DR-D3 and DR-D2, as DR-D3 sig-
naling in CD4 T cells is associated with inflammation
(IFNγ), while DR-D2 signaling with regulation of im-
mune responses (IL-10) [69]. Interestingly, the absence
of DR-D3 in CD4 T cells protects from MPTP-induced
neuroinflammation [50], and DR-D2 knockout mice de-
velop PD-like features [51]. This suggests that changes
(See figure on previous page.)
Fig. 8 Percentage of microglia expressing diverse activation markers. a Representative dot plots showing the gating strategy for live CD11b+ cells.
Bar graphs representing the average percentage + SD of microglia expressing activation markers related to tolerance (b) or adaptive immunity (c).
Tables showing the average percentage of co-expression between pairs of activation markers at low dose (d, f) and high dose (e, g), as well as
adjuvant (h) and naive (i). Markers co-expressed in less than 30 % of the population are in blue (considered to have an independent expression),
and those co-expressed in 70 % or more are in orange (considered to have a correlated expression). One-way ANOVA followed by Tukey HSD.
Asterisk means different from naive; A means different from adjuvant; dagger symbol means different from naive and adjuvant; open circle means
different from the other α-syn variant independent of dose; not equal to symbol means different from all; plus-minus sign means different from
the same α-syn variant at different dose; dollar sign means different from the other α-syn variant at the same dose; double dagger symbol means
different from the other α-syn variant at a different dose. p < 0.05. n = 8–10, divided into three independent experiments
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in dopamine levels during PD may crucially affect the
peripheral immune system, in particular because these
two receptors have very different affinities for dopamine,
and thus if dopamine becomes scarce in PD, it will pref-
erentially bind to DR-D3 (Ki ≈ 27 nM vs. 1705 nM for
DR-D2, [74–76]). A recent paper showed that DR-D3
stimulation reduced cAMP levels and ERK2 phosphoryl-
ation consequently increasing CD4+ T cell activation
and Th1-differentiation, respectively [77]. We observed
here an increase in in DR-D3+ CD4 T cells in mice vac-
cinated with low-dose α-syn compared to naive in both
the Treg and Th pool, again suggesting that low-dose α-
syn boosts regulation of immune responses, and its sig-
naling may have contributed to the expansion of naive
Treg.
Surprisingly, the expression of CD103 and CCR6 was
only observed in cells expressing DR-D2 and DR-D3, as
effector cells negative for DRs were CCR6-CD103-, and
these markers were expressed by only 10 % of the DR-D2/
D3-negative Foxp3+ cells. This suggests a physiological
function for both dopamine and α-syn in T cells, after all
it is known that T cells express α-syn [35]. Of particular
notice is the relation between DR-D2/D3 and CCR6 on
Tregs because not only does it denote activation; it also al-
lows Tregs to migrate. Indeed, low-dose α-syn reduced
the expression of CCR6 on DR-expressing cells and
induced CD103 specifically on DR-D3+ cells. This is a
dose-specific effect, as at high α-syn dose, CD103 was up-
regulated in both DR populations. As mentioned above,
CD103 is considered a marker for Treg memory; thus, our
findings suggest that α-syn at low dose acts differently in
DR-D2+ and DR-D3+ Tregs, promoting respectively acti-
vation/migration and memory induction, as well as in-
creasing their capacity to mediate suppression through
cell-cell contacts in both cases.
Microglia respond to peripheral immune changes induced
by α-synuclein
One of the remarkable findings of this study is that per-
ipheral α-syn immunization modified brain microglia.
This was dose-dependent and occurred despite the ab-
sence of any brain α-syn pathology, as a low dose of α-
syn induced microglia polarization but not a high dose.
This effect was variant-dependent, as Nα-syn had dis-
tinct effects on brain microglia. The phenomenon that
microglia are affected by peripheral immune events,
modulating how they handle ongoing neurodegenerative
processes in brain, is well documented (for a review see
[78, 79]). Our cytometric analysis included full brain
microglia; however, our immunohistological data suggest
that the microglia response is anatomically specific, with
substantia nigra being particularly sensitive to changes
in the peripheral immune system. This is particularly in-
triguing from a PD perspective since although α-syn
pathology extends throughout the patient’s brain, it is
mainly the dopaminergic neurons in substantia nigra
that die, and this is also an important site of chronic
microglia activation. The idea that microglia protein ex-
pression is anatomically heterogeneous, even under
surveillance/homeostatic state, is not a novel concept
[80, 81]. Some markers expressed by microglia are
immunoregulatory, such as CD80/CD86, which gives co-
stimulation to T cells, indicating that the brain is natur-
ally equipped to interact with the peripheral immune
system [82]. In PD patients, depending on the disease
stage, different cytokines, T cells, and CD68 microglia
have been observed in different brain regions [83]. This
time-and-region specificity has also been seen in PD ani-
mal models [84, 85]. Whether this region specificity is
related to higher α-syn levels in substantia nigra
(reviewed in [86]), a difference in the neuronal ability to
signal to the immune system, or to an intrinsic suscepti-
bility of nigral microglia to peripheral immune changes
is yet to be determined. However, our study suggests
that α-syn in a low dose induces a specific type of micro-
glia that co-expresses CD54 and CD172a, and at least
half of this population is also CD4CD103+; thus, this
type is distinct from the microglia observed under the
other conditions tested. What this means for protection
against α-synucleopathies is early to say, but it is well
known that CD172a (SIRPα) regulates innate immune
responses [87] and TNF production [88]; additionally, it
has been involved in restricting neuroinflammation
(reviewed in [89]). CD54 (ICAM-1) binds LFA-1 on T
cells [90], so the generated microglia has the capacity to
bind to T cells, but not to activate them, as the microglia
generated do not express MHC II. This could therefore
result in a situation where the generated microglia se-
quester T cells and prevent their activation. T cells will
then neither be activated nor available for activation by
an antigen-presenting cell. Lastly, CD103 expression by
dendritic cells has been associated with the generation
of Tregs [91, 92]. Thus, this type of microglia seems to
have the potential to promote interactions with the
adaptive immune system and hinder its activation, while
also inhibiting innate immune processes, which is in
concordance with the expansion of Treg cells in the per-
iphery. These interactions may prove crucial for disease
progression, as well as vaccination strategies; indeed, a
study has recently been published showing lymphatic
vessels surrounding the brain and draining directly to
deep cervical lymph nodes [93].
An interesting observation is that although microglia
expressing CD40L (CD154) were increased, it did not
correlate with the other markers. CD40L gives microglia
the putative ability to interact with B cells by binding
CD40. Normally, CD40-CD40L induce B cell matur-
ation, IgG production, and memory induction, but it also
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requires TCR binding of MHC II on B cells. This ability
could be crucial to neuron survival, depending on
whether CD40L+ microglia-B cell interactions result in
the sequestering (due to lacking additional signals) or ac-
tivation (induction of a humoral response in absence of
T cells) of the B cells, as antigen deposition on dopamin-
ergic neurons has been inversely correlated with neur-
onal survival [94].
Can an α-synuclein-based immune therapy prove effective
in Parkinson’s disease?
Our previous studies [3] and those from the group of
Gendelman in the MPTP model [4, 95, 96] seem to indi-
cate that correct priming of T cells, in particular the Treg
compartment, may harness neuroinflammation and thus
protect dopaminergic neurons. This theory has been fur-
ther supported by the effects seen on adaptive immunity
and microglia responses in the DR-D3 knockout MPTP
mouse model, which further links detrimental CD4 T cell
processes with dopamine signaling [50]. Indeed, animals
lacking lymphocytes or CD4 T cells are partially protected
against MPTP neurodegeneration [97]. Thus, we believe
that a possible way to prevent/slow dopaminergic cell
death is a vaccine therapy aimed to increase tolerance to-
wards α-syn and modulate the microglia response. Why
do we believe that such a therapy can prove beneficial
when clinical trials using vaccination for Alzheimer dis-
ease were unsuccessful? We believe the immune processes
happening in Alzheimer’s disease and in PD are putatively
of very different nature, and what is protective (or detri-
mental) in one disease will not necessarily produce the
same effect in the other. Whereas the strategy for Alzhei-
mer’s disease has been to activate the immune system to
react towards Aβ deposits, it is our hypothesis that a suc-
cessful immunotherapy for PD will raise tolerance to α-
syn, so that the brain can better handle the detrimental ef-
fects caused by α-syn malfunction/aggregation instead of
initiating an auto-inflammatory response to eradicate the
problem (i.e., malfunctioning neurons). Thus, the failure
observed in the trials for Alzheimer’s disease vaccination
does not necessarily herald defeat for PD. Furthermore,
depletion of Tregs (i.e., breaking tolerance) is beneficial in
a mouse model of Alzheimer’s, thus showing that the im-
mune processes are indeed different in these neurodegen-
erative diseases [98].
Conclusions
Our data shows distinctive immune responses upon the dif-
ferent immunization strategies. These responses were
unique to the antigen (α-syn variants) and dose and were
not mere standard immune responses to any type of anti-
gen. Indeed, we have observed that a non-disease relevant
peptide such lipopolysaccharide (LPS), a well-known proin-
flammogen, results in a significantly different response in
the T cells (Olesen, Christiansen, Jensen, Otzen, Romero-
Ramos and Sanchez-Guajardo, Submitted). This is in agree-
ment with a previous study comparing the immune re-
sponse after intracerebral injections of α-syn or LPS [99].
Furthermore, several groups have reported different im-
mune responses in macrophages/microglia for the different
type of α-syn (for a review see [60]).
We show herein that CD4 T cell profiles can be modu-
lated by α-syn (with adjuvant) in a dose-dependent man-
ner: α-Syn in a low dose expands the naive Treg
population, thus suggesting that the mechanism behind
our previously described successful vaccine approach was
due to the induction of increased tolerance to α-syn. This
immune modulation is dose-dependent, since increasing
the dose of α-syn resulted in the expansion of the acti-
vated Treg pool. We have further shown that α-syn stimu-
lation of T cells involves dopamine signaling in a yet
undetermined manner regulating CD4 T cell homing and
capacity to induce tolerance. Of particular interest is the
relation of dopamine receptors and CCR6 expression, as
all Th17 cells are CCR6+, and so are memory Tregs. Add-
itionally, CCR6 signaling has been implicated in the con-
version of Tregs into Foxp3+RORγt+ cells [100]. These
events in the periphery affected microglia phenotype in the
absence of brain α-syn pathology, also in a variant- and
dose-dependent manner. Microglia modulation was neither
due to CD4 T cell infiltration nor antigen deposition, and it
was particularly different in substantia nigra as shown by
morphological changes of immunostained microglia. We
have thus shown that the immune system is sensitive to
changes in α-syn and that antigen-specific immunoregula-
tory therapies based on modulating microglia responses by
acting on the peripheral immune system are possible.
Additional files
Additional file 1: Table S1. Antibodies. (PDF 158 kb)
Additional file 2: Figure S1. CD11b immunohistochemistry.
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α-syn high-dose group’s hippocampus was sporadic mouse IgG staining
observed (F); however, blood vessels in all groups stained positive for IgG
(G). A, C, D & F: ×20 magnification, scale bar in E, 10 μm. B, E, G: ×10
magnification, scale bar in D, 100 μm. (PDF 2.38 mb)
Additional file 4: Figure S3. α-Synuclein immunohistochemistry.
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